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took and what additional evidence was requested. Data on 19 projects that entered 
phase III and 30 products achieving first world approval from 2009-2012 were ana-
lysed. Results: For the phase III projects, 63% received HTA scientific advice, of 
which 61% occurred during phase II, with company-sponsored advisory boards 
the being most frequent provider. The main HTA-related requirements included 
in development were patient-reported outcomes (84%), HTA-acceptable endpoints 
(74%), and cost-effectiveness analysis (74%). For licensed products, the median 
time from regulatory submission to reimbursement decision varied from 639 days 
(Australia) to 846 days (Italy). Additional comparators for local HTA submission were 
requested by all jurisdictions except USA. England and France showed the highest 
percentage of products being reimbursed as per the regulatory label (50% and 55% 
respectively). ConClusions: Companies are actively taking scientific advice and 
incorporating HTA requirements into their development process, although they are 
still challenged by divergence in HTA process and decision making across jurisdic-
tions. Benchmarking HTA processes at the product level supports companies in 
driving excellence in risk management and strategic planning.
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objeCtives: The special committee of cost-effectiveness at the Japanese health 
ministry advisory panel was established in 2012 and the need for economic evalu-
ation guidelines was proposed. The research team funded by the Japanese Ministry 
of Health, Labour and Welfare published the guidelines for economic evaluation of 
health care technologies in 2013. We compared the Japanese guidelines to existing 
guidelines in other Asian countries and to the NICE guidelines (UK). Methods: We 
searched for and reviewed the Japanese research report and guidelines published 
in China, Taiwan, Thailand and South Korea up to February 2014. Similarities and 
differences between Japanese guidelines and those from other Asian countries as 
well as NICE guidelines were identified. Results: Pharmacoeconomic evaluations 
are mandatory in the UK, South Korea and Thailand, recommended in Taiwan, and 
optional in China. In Japan, economic evaluations are currently not formally consid-
ered in pricing and reimbursement decisions. Japanese guidelines are relatively open, 
leaving much room for decision from analysts. Guidelines from different countries 
were broadly consistent in terms of preferred analytical technique (cost-effectiveness 
analysis), need of systematic reviews of evidence and consideration of effectiveness 
data as well as efficacy; but varied in terms of primary perspective for estimating costs 
(third-party payer in Japan), preferred outcome measure (no systematic use of QALYs 
in Japan, other measures, such as laboratory values, also accepted), preferred methods 
to derive utility values (generic instruments with scoring algorithm developed in 
Japan), and sensitivity analysis methods (probabilistic sensitivity analysis “when pos-
sible”). ConClusions: This comparative exercise provides an overview of economic 
evaluation guidelines adopted by 5 Asian countries and UK. The recommendations 
differed in some aspects, but Japanese guidelines are relatively open, which should 
facilitate adaptations of models between countries. One of the hurdles for adapting 
models is likely to be the variability in approaches recommended to obtain utilities.
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objeCtives: A rapid growth of health technology assessment (HTA) activities 
among researchers and physicians in Japan is observed since the mid-1980s. 
However, Japan lags behind Europe, Australia, and several Asian countries in imple-
menting national HTA regulations. Although it is generally accepted that low health 
care costs and good health prevail in Japan, population aging, rising costs of medical 
technologies and slow economic growth rates necessitate rethinking the current 
HTA regulations. This study aims to evaluate the history and current situation of 
the Japanese HTA system, and what Japan needs to do in order to successfully 
implement national HTA regulations. Methods: Past and current Japanese HTA 
regulation are assessed by analysing both English and Japanese publications and 
legal documents, as well as comparing these with the systems in other Asia-Pacific 
countries: Australia, South Korea, Taiwan, Thailand. Results: There are historical, 
social, and biological reasons why Japan has been successful at maintaining the 
world’s longest life expectancy and the lowest infant mortality at relatively low cost 
despite the lack of a comprehensive HTA system. However, implementation of HTA 
regulation would be a key lever in the health system in line with the new economic 
policy introduced by Prime Minister Abe in 2012. Looking at the legal and organisa-
tional structures, implementation and performance of Asia-Pacific HTA systems, 
a comprehensive HTA system for Japan is proposed. ConClusions: HTA systems 
have been rapidly developing in the Asia-Pacific over the last decade. Facing the 
current pressures on the health system, the question is not whether Japan should 
introduce a comprehensive HTA system but what measures she should adopt. The 
experience of other Asia-Pacific countries in implementing national HTA systems 
can help inform the development of an innovative national HTA system in Japan 
that could play a central role in the future of Japanese health care.
HEaltH CarE usE & PoliCy studiEs – Population Health
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dations by these is likely to be influenced by factors other than process taxon-
omy. ConClusions: This study identified the greatest level of congruence for HTA 
recommendations from the A taxonomy agencies. Other factors likely play a role in 
the divergences of reimbursement recommendations among dissimilar taxonomies, 
which could be better understood by refining the HTA taxonomy characteristics.
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objeCtives: Da Vinci Surgical System (DVSS) is the most widely studied surgical 
robot in recently years, which is developed to assist surgeons performing surgical 
procedures. However, DVSS is associated with high capital and operating costs. 
Given its limitations, a review of clinical and economic evidence is necessary for 
decision-makers. we conducted a rapid review to evaluate the clinical and cost-
effectiveness of DVSS compared with open procedures and laparoscopic procedures, 
in order to provide the evidence for health decision makers. Methods: A compre-
hensive search of electronic databases (EMBASE, PubMed, Cochrane Library, Web of 
Science, CINAHL, CNKI, VIP, CBM and Wangfang) and HTA websites were completed 
to October 9, 2013. Two trained reviews independently screened for eligible studies, 
extracted data and assessed quality. Qualitative description was used to report the 
outcomes. Results: After an initial screen of 272 studies, 18 studies (n= 45,516) 
were selected for meeting inclusion criteria: 3 studies with 32,499 patients were 
healthy technology assessments and 15 studies with 13,017 patients were system-
atic reviews. The clinical and cost-effectiveness of DVSS was varied between dis-
eases. Overall, DVSS was shown to be associated with a reduction in operative time, 
length of hospital stay, blood loss, and transfusion rate compared with open and 
laparoscopic surgery on prostatetomy, nephrectomy, and hysterectomy colorectal 
surgery. DVSS was more expensive than open and laparoscopic surgery for the cost 
of acquiring, operating, and maintaining the robotic techniques. Most economic 
studies showed no significant difference was found in cost- effectiveness of DVSS 
comparing with comparators. ConClusions: DVSS may have an impact on several 
clinical outcomes. However, the evidence was limited to systematic review and 
healthy technology assessments. Furthermore, the cost of DVSS is higher than open 
and laparoscopic surgery. Taking all of this evidence together, decisions about the 
robot-assisted surgery need to be made carefully.
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objeCtives: Local pharmacoeconomic evidence was seldom included in the manu-
facturers’ new drugs submission in Taiwan before. A series of pragmatic strategies 
were employed to encourage the presentation of local cost-effectiveness analysis 
(CEA) evidence in the dossiers. This study aims at examing the performance of these 
strategies. Methods: An incentive of mark-up for conducting local CEA studies has 
been announced since 2010 to encourage the pharmaceutical manufacturers to sub-
mit CEA evidence for new drugs reimbursement application. The National Institute of 
Health Technology Assessment (NIHTA) has started to use a self-developed checklist 
to assess the quality of the local CEA evidence presented in the dossiers. The appraisal 
committee would then decide the extent of mark-up based on the assessment results. 
Three epochs were defined as (1) before mark-up epoch: 2008-2009 (No Mark-up 
Epoch), (2) mark-up without checklist epoch: 2010-the mid-2012 (No Checklist Epoch), 
and (3) mark-up with checklist epoch (Checklist Epoch): mid-2012 till 2013. The num-
ber and the quality of local CEA evidence identified from the dossiers submitted by 
the manufacturers in the three epochs were compared. Results: In the No Mark-up 
epoch, none local CEA evidence has been presented in the dossiers. However, 5 and 
7 local CEA studies have been identified from the dossiers in the Mark-up epoch and 
the Checklist epoch, respectively. None out of the 5 local CEA studies has received the 
mark-up, nevertheless, 6 out of the 7 local CEA studies have receive 1% to 5% mark-
up for the reimbursement price. ConClusions: The pragmatic strategy seems an 
effective approach to encourage the manufacturers to present local CEA evidence in 
the dossiers, which could improve the quality of decision making. In addition, the 
capacity of conducting local CEA studies has been gradually established.
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objeCtives: To evaluate the impact of HTA on the development and market access 
of new pharmaceutical products in Australia, Canada, England, France, Germany, 
Italy, Spain and the USA. Methods: An annual benchmarking study was devel-
oped in collaboration with 9 multinational pharmaceutical companies to establish 
appropriate developmental performance metrics to identify if scientific advice 
was received, when it was received, from whom and the outcome and specific 
HTA requirements included into the development process. In addition data were 
also collected across 8 jurisdictions (Australia, Canada, England, France, Germany, 
Italy, Spain and the USA) to identify what evidence was submitted, the time it 
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 7 1 9 – A 8 1 3  A799
PHP91
CurrEnt status and dEfiCiEnCy of HEmostasis in surGEry: a 
systEmatiC litEraturE rEviEw, inCludinG CHinEsE litEraturE
Tsao J.1, Chen X.J.2, Yue N.2
1Johnson & Johnson Medical Asia-Pacific, Singapore, 2Johnson & Johnson Medical China, Beijing, 
China
objeCtives: Perioperative bleeding sometimes results in severe consequence. An 
understanding of hemostasis approaches is crucial in managing the operations. This 
review aims to show the development of hemostasis in surgery around the world 
including China. Methods: Literature in PUBMED was searched between 2009 
and 2014; search terms included hemostasis and surgery; filters included human, 
English and clinical trials. A similar search was done in Chinese CNKI database. 
Searching results were carefully reviewed and studies compatible with our inclu-
sion criteria were then selected. Results: From an initial search which yielded 
99 references in PUBMED and 50 references in CNKI, 54 articles in PUBMED and 16 
articles in CNKI were included in the review. Operations in 11 subjects were involved 
in these articles. We found that conventional hemostasis (classic technique of tying 
and knots, resorbable ligature) was gradually replaced by novel techniques such 
as bipolar tissue sealant device, ultrasound scalpel, hempclips, blue-violet light 
emitting diode irradiation, Ankaferd Blood Stopper, etc. Fibrin sealant, collagen 
hemostat and chitosan gel had important roles to be supplement. Certain drugs 
(tranexamic acid, Fibrinogen concentrate, hemocoagulase, etc) used perioperatively 
could be efficient too. On the other hand, some new techniques (vascular clips) 
failed to show significant benefits in some subjects (thyroid surgery). Furthermore, 
some techniques (bipolar coagulation) might affect the postoperative function of 
certain organs (ovary). While some techniques (harmonic scalpel) could save the 
whole cost in hospital, most could not. Information in China was similar with the 
world. ConClusions: Some of the novel hemostasis approaches in surgery could 
decrease blood loss perioperatively as well as reduce operative time, hospital stay, 
the rate of complications and the whole cost. However, some shortcomings still exist 
and more correlative researches should be performed in the future.
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objeCtives: Pharmacoeconomics is a newly developed discipline in China. 
Economic assessment is increasingly used as supportive evidence driving pricing 
and reimbursement decisions. Nevertheless, guidelines are necessary to homog-
enise their practice and promote their use. Among the different guidelines that 
have been published, two published in 2006 and in 2011 significantly support the 
implementation of pharmacoeconomics in China. Since multinational pharma-
ceutical companies are increasingly present in the Chinese market, this tends to 
increase the spread of such publications. This paper aims to quantify the impact 
of the introduction of guidelines as incentives to publish international articles in 
China. Methods: A literature review was undertaken using the Pubmed data-
base. Keywords used in the search strategy were: ‘China’, ‘Pharmacoeconomics’, 
‘Economic Evaluation’, ‘Cost-Effectiveness’, ‘Cost of Illness’, ‘Cost-Benefit’, ‘Cost-
Utility’, ‘Cost-Minimization’ and ‘Budget Impact’. We used a timeframe of ten 
years before the first pharmacoeconomic guideline to present. This corresponds to 
01/01/1996 to 14/03/2014. In order to take into consideration only international publi-
cations, only English papers were selected. A final screening was performed to select 
the articles directly related to pharmacoeconomics and only in China. Results: 
272 articles were found with the primary search strategy and 99 were selected using 
the final critera. On average, 1 paper was published every year until 2006 while 8 
were published between 2006 and 2010, and 16 after 2010. The publications’ pace 
increases exponentially from 2011 to finally reach 19 publications in 2013. In the 
first ten weeks of 2014, 9 articles are already particularly intense, which can be 
interpreted as real trend. ConClusions: This study reveals a correlation between 
pharmacoeconomic guidelines and volume of publications. Even if the place of 
this new discipline remains minor because of the initial level of submission, sig-
nificant efforts are undertaken to submit and use pharmacoeconomic studies as 
fully-fledged, leading to pricing and reimbursement decisions.
HEaltH CarE usE & PoliCy studiEs – Quality of Care
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objeCtives: It has been shown in literatures that full-time intensivists improve the 
quality of patient care and reduce medical resource utilization. The study compares 
the quality of care in Respiratory Care Center (RCC) staffed by full-time intensiv-
ists (no outpatient clinics), part-time responsible chest physicians (with duties in 
outpatient, inpatient, and RCC) and full-time responsible chest physicians (with at 
most 3 half-day outpatient clinics per week besides WCC) and predicts risk factors 
for mortality and weaning rates in RCC patients. Methods: Retrospective data 
were collected and analyzed from all RCC patients in a medical center cared for 
by full-time intensivists from 2004 to 2005, part-time responsible chest physicians 
from 2008 to 2009, and full-time responsible chest physicians from 2011 to 2012 
to determine whether there were differences in the quality of care and predict 
risk factors for mortality and weaning in RCC patients. Results: There were 2,757 
patients in the study with an average age of 69 years, APACHE II scores of 16.68, mor-
tality of 23.90%, weaning rates of 50.68% and complication rate of 40.74%. Patients 
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objeCtives: As medical representative’s job involves travelling, waiting, stress 
due to targets and extended work hours in the field, their health related qual-
ity of life may be compromised. There are no studies reporting health related 
quality of life, an exploratory study was done to understand factors influencing 
health related quality of life. Methods: In this exploratory study a pilot tested 
questionnaire was used to collect information regarding medical representatives’ 
characteristics, demographics, work and life habits. For health related quality of 
life measurement both descriptive and visual analogue score of EQ 5D 5L ques-
tionnaire were used. The data collected was analyzed using SPSS 16.0.0. The test 
of significance was done by using Kruskal-Wallis test. Results: This is a part 
of large group study which is underway to record health related quality of life 
among medical representatives, the results presented here are of 150 medical 
representatives. Mean age of the population studied was 27.58±4.6, 25% having 
more than 4 family dependents and 53 % were science graduates. 59.3% worked for 
more than 8 hours per day. 45.3% were not involved in doing any physical activity. 
Mean BMI was 23.52±3.45 and VAS score was 84.46±12.59. There was significant 
difference of VAS score among the groups involved in doing and not doing any 
physical activity (p< 0.001). ConClusions: Even though the population studied 
was young, involvement in physical activity makes a difference in their health 
related quality of life.
HEaltH CarE usE & PoliCy studiEs – Prescribing Behavior & treatment 
Guidelines
PHP89
tHE imPaCt of unfamiliarity in PalliativE CarE undEr 
PHarmaCotHEraPEutiC asPECt
Juang H.J.1, Diamente L.M.2
1Hospital Municipal, São Paulo, Brazil, 2Hospital Municipal, SÃO PAULO, Brazil
objeCtives: The perception and the knowledge of health care at the end of life is 
the fundamental key to prevent an aggressive and useless therapy to patients at 
this stage of life and even more, which may cause more suffering to patients and 
burden the health care expenditures. This study aims to point out the possible 
impact of unawareness in palliative care under the pharmacotherapeutic aspect 
to help subsidize the development of improvement programs in this new medi-
cal area. Methods: This study was conducted in 2013, in a mid-sized public and 
teaching general hospital, located in Sao Paulo, Brazil. It was based on direct critical 
assessment of medical prescription sheets of 15 patients classified as terminally ill-
ness and should receive palliative care Results: Approximately half of the patients 
were admitted to the intensive care unit, 66% were medical patients and 33% are 
surgical, almost of them all were adult patients (93.3%). All of them received non-
opioid analgesics and antipyretics; 80% received antacids and anticoagulants drugs; 
66.6% received hypoglycemic drugs; 53.3% received antimicrobial and antihyper-
tensive drugs; 46.6% received vasoactive drugs; 40% received opioids, cardiotonic 
drugs and statin therapy. And 33% patients received antiplatelet drugs and blood 
products; 26.6% received muscle relaxant drugs, and only 20% received corticos-
teroids ConClusions: As we found only few prescriptions asking for opioids and 
benzodiazepines, but there were more frequently to vasoactive drugs, we can say 
that many therapeutic resources are still wrongly applied to patients classified as 
terminals. And as well as they receiving untimely and costly treatments, unfortu-
nately these efforts do not bring true compatible with their benefit needs, just is 
physical pain relief and anxiety reduction. Thus, it is essential to promote efforts 
to disseminate and clarify what is palliative care and how to provide more rational 
and humane care to these patients.
PHP90
study of antiBiotiC PrEsCriPtion PattErn and antiBiotiC sEnsitivity 
in surGEry PatiEnt in tErtiary CarE HosPital
Lalwani T.1, Adhvaryu G.1, Joshi D.1, Deshpande S.S.2, Shah G.B.1
1K. B. Institute of Pharmaceutical education and research, Gandhinagar, India, 2KB Institute of 
Pharmaceutical Education and Research (KBIPER), Gandhinagar, India
objeCtives: Primary Objective: – To study prescription pattern of antibiotics as 
prophylactic and in post surgery infection. Secondary objective: – To determine 
antibiotic sensitivity pattern in bacterial isolate Methods: The study was a pro-
spective study for a period of four month from Jan-May 2013, Prescriptions and 
patient records files are reviewed and analyzed. Prescription pattern and antibiotic 
sensitivity was also evaluated. Results: Total 154 patients were included in our 
study from these 59% were male (n= 91) and 41% were female (n= 63). Total 19 dif-
ferent antibiotics were prescribe in general surgery in which Amikacin (n= 106, 
69%), ceftriaxone (n= 104, 67%) and metronidazole (n= 72, 47%) are most com-
monly prescribed antibiotics. Most of the patient had undergone hernioplasty 
surgery (n= 33, 22%) followed by Incision & Drainage (n= 23, 15%), debridement 
(n= 21, 14%), Appendicectomy (n= 16, 10%). Pus swab culture (44%) are done most 
frequently followed by wound culture (n= 13, 24%), urine culture (n= 9, 17%) in 
culture and sensitivity test. Most common isolate were klebsiellia sp. (n= 12, 31%), 
followed by S. aureas (n= 9, 21), E. coli (n= 8, 19%) which are resistant to ampicillin, 
amoxicillin, carbenicillin, ceftriaxone, cefuroxime, ceftazidime and cefotaxime 
and sensitive to levofloxacine, gatifloxacine and amikacin. ConClusions: There 
was high tendency to prescribe the 3rd generation cephalosporins. Physicians pre-
scribed ceftriaxone antibiotic as prophylaxis for hernioplasty, appendectomy and 
Lap. Cholecytectomy. Most of the patients admitted to surgery unit had received 
antibiotic without regard to Culture Sensitivity report and standard guidelines. 
E. coli isolates were found to be 100% resistant to all penicillins, 3rd generation 
cephalosporins, cotrimoxazole and amoxiclav and Klebsella species were found 
to be 100% resistant to ampicillin.
